insights_auto
Por qué ha subido 688235 4,06%?
Profundizarchevron_right
688235:SHA
BeOne Medicines AG
255,98 CNY
arrow_upward
+4,06%(+9,99) 1 d
16 oct, 15:00:00 GMT+8 · CNY
search
Todos los símbolos
| Símbolo | Precio | Cambio | % de cambio |
|---|
insights_autoGenerando estadísticas principales de 688235...
Abrir
253,20 CNY
Alto
268,18 CNY
Bajo
252,09 CNY
Cap. burs.
289,03 mil M
Vol. medio
2,81 M
Volumen
5,69 M
Ratio PER
91,43
Máximo en 52 sem.
319,24 CNY
Mínimo en 52 sem.
205,51 CNY
BPA
2,80 CNY
N.º de empleados
12 mil
Abrir
253,20 CNY
Alto
268,18 CNY
Bajo
252,09 CNY
Cap. burs.
289,03 mil M
Vol. medio
2,81 M
Volumen
5,69 M
Ratio PER
91,43
Máximo en 52 sem.
319,24 CNY
Mínimo en 52 sem.
205,51 CNY
BPA
2,80 CNY
N.º de empleados
12 mil
Noticias
De fuentes web y partners de noticias
Perfil
BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment.
Founded in 2010 by chief executive officer John V. Oyler and Xiaodong Wang, the company is headquartered in Cambridge, Massachusetts and has locations on six continents, in over 45 countries. BeOne has a large presence in the Chinese market.
BeOne Medicines has developed several medicines, including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor. On 14 November 2024, the company announced its intention to rebrand as BeOne Medicines. BeOne changed its stock ticker to ONC in January 2025 and redomiciled to Basel, Switzerland in May 2025. Wikipedia
Acerca de BeOne Medicines AG
CEOJohn Vincent Oyler | John Vincent Oyler
Empleados12 mil
Fundación28 oct 2010
Sede-
Sector-
Sitio webbeonemedicines.com